Business Wire: October 24, 2016 – STOCKHOLM, Sweden – Braeburn Pharmaceuticals and Camurus (STO: CAMX) today announced the expansion of their collaboration and license agreement from 2014 to include buprenorphine combination products. The first drug candidate within the expanded scope (CAM2058) is…
